Development of porphyria cutanea tarda in a chronic hepatitis C patient with indetectable viremia under treatment with peg-interferon plus ribavirin;Aparición de porfiria cutánea tarda durante el tratamiento con peg-Interferón más ribavirina en un paciente con hepatitis C crónica con viremia indetectable

Acta Gastroenterologica Latinoamericana

Volumn 36, Issue 1, 2006, Pages 38-41

  Frider, Bernardo ^a   Buonsante, María Eugenia ^a   Tiscornia, Jorge ^a   Alessio, Analía ^a   Pellerano, Graciela ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Hemochromatosis; Hepatitis C; Interferon; Porphyria Cutanea Tarda; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ARTICLE; CASE REPORT; GENETICS; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; PORPHYRIA CUTANEA TARDA; VIROLOGY;

ANTIVIRAL AGENTS; HEMOCHROMATOSIS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PORPHYRIA CUTANEA TARDA; RIBAVIRIN;

EID: 33645661649     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998;18:67-75.
2. Herbert L, Bonokovsky MD, Savant Mehta MD. Hepatitis C: A review and update. J Am Acad Dermatol 2001; 44:159-179.
3. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alfa therapy in a case of chronic hepatitis C. Dig Dis Sci 1998;43:529-533.
4. Takihawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful Interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995;22:249-250.
5. Jessner W, Der-Petrossian M, Christiansen L, et al. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology 2002;36:1301-1302.
6. Thevenot T, Bachmeyer C, Hammi R, Dumouchel P, Ducamp-Posak I, Cadranel J. Ocurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C. J Hepatol 2005;42:607-608.
7. Herrero C, Vicente A, Bruguera M, et al. Is hepatitis C virus infection a tigger of porphyria cutanea tarda? Lancet 1993;341:788-789.
8. Fargion S, Piperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992;16:1322-1326.
9. Chuang T, Brashear R, Lewis C. Porphyria cutanea tarda and hepatitis C virus: A case-control study and meta-analysis of the literature. J Am Acad Dermatol 1999;41:31-36.
10. O'Reilly FM, Darby C, Fogarty J, et al. Porphyrin metabolism in hepatitis C infection. Photodermatol Photoimmunol Photomed 1996;12:31-33.
11. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-1669.
12. Méndez M, Rossetti M, Batlle A, Parera V. The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population. J Am Acad Dermatol 2005;52:417-424.
13. Lopez Morante A, Saez Royuela F, Martin Lorente J, y col. Infección por el virus de la hepatitis C y porfiria cutánea tarda. Gastroenterología y Hepatología 1995;18:7-10.
14. Fargion S, Fracanzani AL. Prevalence of hepatitis C virus infection in porphyria cutanea tarda. Hepatology 2003;39: 318-326.
15. Gisbert JP, Garcia-Buey, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tard: systematic review and meta-analysis. J Hepatol 2003; 39:620-627.
16. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004;19:1312-1317.
17. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. Hepatol 1994;21:1109-1111.
18. Rulyak SJ, Eng SC, Patel K, McHutchison JG, Gordon SC, Kowdley KV. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with Interferon and ribavirin. Am J Gastroenterol 2005;100:332-337.
19. Hofer H, Osterreicher C, Jessner W, Penz M, Steindl-Munda P, Wrba F, Ferenci P. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients widi chronic hepatitis C. J Hepatol 2004;40:1018.
20. Fernandez I, Castellano G, De Salamanca RE, et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 2003;38:314-319.
21. Castillo I, Rodriguez-Inigo E, Bartolome J, et al. Hepatitis C virus replicate in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005;54:682-685.